Abstracts tagged "nephritis and vasculitis"

Abstract Number: 3045 • 2016 ACR/ARHP Annual Meeting
Immunometabolism in ANCA-Associated Glomerulonephritis
Peter C. Grayson¹, Sean Eddy², Viji Nair², Hemang Parikh³, Maja Lindenmeyer⁴, Laura Mariani², Huateng Huang², Wenjun Ju³, Casey Greene⁵, Clemens Cohen⁴, Jeffrey Krischer³, Matthias Kretzler², Peter A. Merkel⁶ and Felix H. Eichinger², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Division of Nephrology, University of Michigan, Ann Arbor, MI, ³University of South Florida, Tampa, FL, ⁴University of Munich, Munich, Germany, ⁵Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Mounting an inflammatory response requires immune cells to undergo major changes in metabolism. Mediators such as cytokines can specifically alter the metabolism of different…
Abstract Number: 3046 • 2016 ACR/ARHP Annual Meeting
Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome
Sean Eddy¹, Viji Nair¹, Hemang Parikh², Maja Lindenmeyer³, Laura Mariani¹, Felix H. Eichinger¹, Huateng Huang¹, Wenjun Ju², Casey Greene⁴, Peter C. Grayson⁵, Clemens Cohen³, Jeffrey Krischer², Peter A. Merkel⁶ and Matthias Kretzler¹, ¹Division of Nephrology, University of Michigan, Ann Arbor, MI, ²University of South Florida, Tampa, FL, ³University of Munich, Munich, Germany, ⁴Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Clinical trials in rare diseases typically test therapeutic efficacy in one disease defined by a particular clinical phenotype. Improved understanding of the molecular mechanisms…
Abstract Number: 733 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Kuninobu Wakabayashi, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Masayu Umemura, Takahiro Tokunaga, Hiroyuki Tsukamoto, Sakiko Isojima, Hidekazu Furuya, Ryo Yanai, Kumiko Otsuka, Ryo Takahashi, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: It is important to determine the biomarkers for assessing disease activity of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Plasma levels of fibrin/fibrinogen…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].